ABVC BioPharma (ABVC) Stock Price, News & Analysis

Company Overview

ABVC BioPharma is a clinical-stage biotechnology company focused on the discovery and development of novel vaccine and immunotherapy candidates for oncology and infectious diseases. The company leverages a proprietary peptide-based platform to identify and synthesize immunogenic epitopes, aiming to stimulate targeted immune responses against tumor-associated and pathogen-derived antigens.

The company’s pipeline includes active immunotherapy programs designed to address a range of cancer indications, along with vaccine candidates targeting bacterial pathogens. ABVC BioPharma applies its platform to generate both personalized and off-the-shelf candidates, with preclinical and early-stage clinical studies evaluating safety, immunogenicity and preliminary efficacy.

Headquartered in Research Triangle Park, North Carolina, ABVC BioPharma operates research laboratories in North America and collaborates with academic and industry partners to advance its development programs. The company’s leadership team is composed of executives and scientists with experience in peptide chemistry, immunology and clinical development, guiding its efforts to bring new vaccine-based therapies to market.

Key Stats

• Today's Range: $0.85 to $1.03
• 50-Day Range: $0.71 to $2.02
• 52-Week Range: $0.71 to $3.40
• Volume: 179,093 shs
• Average Volume: 107,579 shs
• Market Capitalization: $26.65 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Sell

ABVC BioPharma Stock Analysis - MarketRank™

ABVC BioPharma scored higher than 7% of companies evaluated by MarketBeat, and ranked 883rd out of 913 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 0.7 / 5
• Analyst Rating: Sell

Consensus Rating

ABVC BioPharma has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.

Amount of Analyst Coverage

ABVC BioPharma has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of ABVC BioPharma is -3.33, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of ABVC BioPharma is -3.33, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

ABVC BioPharma has a P/B Ratio of 2.17. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

1.99% of the float of ABVC BioPharma has been sold short.

Short Interest Ratio / Days to Cover

ABVC BioPharma has a short interest ratio ("days to cover") of 3.52, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in ABVC BioPharma has recently decreased by 2.79%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

ABVC BioPharma does not currently pay a dividend.

Dividend Growth

ABVC BioPharma does not have a long track record of dividend growth.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

News Coverage This Week

MarketBeat has tracked 1 news article for ABVC BioPharma this week, compared to 1 article on an average week.

MarketBeat Follows

1 people have added ABVC BioPharma to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, ABVC BioPharma insiders have not sold or bought any company stock.

Percentage Held by Insiders

19.00% of the stock of ABVC BioPharma is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

11.38% of the stock of ABVC BioPharma is held by institutions.

Company Calendar

• Last Earnings: 8/12/2026
• Today: 9/03/2026
• Next Earnings (Estimated): 11/16/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: NASDAQ:ABVC
• CIK: 1173313
• Web: www.abvcpharma.com
• Phone: (510)-668-0881
• Fax: N/A
• Employees: 30
• Year Founded: 2002

Profitability

• EPS (Trailing Twelve Months): ($0.30)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$7.91 million
• Net Margins: N/A
• Pretax Margin: -954.77%
• Return on Equity: -47.68%
• Return on Assets: -30.97%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.07
• Quick Ratio: 0.07

Sales & Book Value

• Annual Sales: $510 thousand
• Price / Sales: 52.25
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.46 per share
• Price / Book: 2.17

Miscellaneous

• Outstanding Shares: 26,650,000
• Free Float: 21,590,000
• Market Cap: $26.65 million
• Optionable: Not Optionable
• Beta: 0.61